Zivo Bioscience Inc (ZIVO) - Total Liabilities
Based on the latest financial reports, Zivo Bioscience Inc (ZIVO) has total liabilities worth $3.85 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore how efficiently does Zivo Bioscience Inc generate cash to assess how effectively this company generates cash.
Zivo Bioscience Inc - Total Liabilities Trend (2000–2024)
This chart illustrates how Zivo Bioscience Inc's total liabilities have evolved over time, based on quarterly financial data. See ZIVO book value for net asset value and shareholders' equity analysis.
Zivo Bioscience Inc Competitors by Total Liabilities
The table below lists competitors of Zivo Bioscience Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Churchill Capital Corp IX Warrant
NASDAQ:CCIXW
|
USA | $10.24 Million |
|
Maming Enam Sembilan Mineral Tbk PT
JK:AKSI
|
Indonesia | Rp131.72 Billion |
|
Tong Hua Holding Public Company Limited
BK:TH
|
Thailand | ฿32.56 Million |
|
Ata Gayrimenkul Yatirim Ortakligi AS
IS:ATAGY
|
Turkey | TL149.18 Million |
|
Waja Konsortium Bhd
KLSE:0102
|
Malaysia | RM27.17 Million |
|
Huize Holding Ltd
NASDAQ:HUIZ
|
USA | $472.74 Million |
|
Quantum BioPharma Ltd.
NASDAQ:QNTM
|
USA | $6.65 Million |
|
Financiere Marjos SA
PA:FINM
|
France | €1.17 Million |
Liability Composition Analysis (2000–2024)
This chart breaks down Zivo Bioscience Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Zivo Bioscience Inc market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.08 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.17 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 6.87 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Zivo Bioscience Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Zivo Bioscience Inc (2000–2024)
The table below shows the annual total liabilities of Zivo Bioscience Inc from 2000 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $2.16 Million | -21.86% |
| 2023-12-31 | $2.76 Million | +29.43% |
| 2022-12-31 | $2.13 Million | -27.62% |
| 2021-12-31 | $2.95 Million | -74.43% |
| 2020-12-31 | $11.53 Million | +32.42% |
| 2019-12-31 | $8.71 Million | -61.63% |
| 2018-12-31 | $22.69 Million | +10.62% |
| 2017-12-31 | $20.51 Million | +42.87% |
| 2016-12-31 | $14.36 Million | +50.04% |
| 2015-12-31 | $9.57 Million | +47.88% |
| 2014-12-31 | $6.47 Million | -45.01% |
| 2013-12-31 | $11.77 Million | +180.85% |
| 2012-12-31 | $4.19 Million | +67.94% |
| 2011-12-31 | $2.49 Million | +93.17% |
| 2010-12-31 | $1.29 Million | -69.16% |
| 2009-12-31 | $4.19 Million | +338.59% |
| 2008-12-31 | $954.74K | -7.33% |
| 2007-12-31 | $1.03 Million | -10.76% |
| 2006-12-31 | $1.15 Million | -7.65% |
| 2005-12-31 | $1.25 Million | +8.16% |
| 2004-12-31 | $1.16 Million | +2424.50% |
| 2003-12-31 | $45.78K | +2761.31% |
| 2000-12-31 | $1.60K | -- |
About Zivo Bioscience Inc
ZIVO Bioscience, Inc., together with its subsidiaries, engages in licensing and selling natural bioactive ingredients derived from its proprietary algae cultures to animal, human, and dietary supplement and medical food manufacturers. The company operates in the biotech and agtech sectors, with an intellectual property portfolio comprising proprietary algal and bacterial strains, biologically act… Read more